姑息治疗对胶质母细胞瘤生存的影响:谁接受了姑息治疗?
基于美国国家癌症数据库2004至2017年85,380例成人组织学确诊的IV级胶质母细胞瘤患者,分析接受姑息治疗的相关因素及其与总生存的关系。结果显示仅3.28%患者接受姑息治疗;接受姑息治疗与生存期缩短相关,未接受姑息治疗者2年总生存率为22% vs 接受者8.8%(P<0.001);接受姑息治疗者中,接受推荐治疗者2年总生存率9.1% vs 拒绝部分或全部推荐治疗者3.8%(P=0.009)。
要点
- 仅3.28%(2803/85380)的胶质母细胞瘤患者接受了姑息治疗。
- 年龄≥70岁、医保、肿瘤≥5cm、多灶性等因素与接受姑息治疗几率增加独立相关。
- 接受姑息治疗者2年总生存率8.8% vs 未接受者22%(P<0.001)。
核心结论
- 在高分级胶质瘤患者中,接受姑息治疗与生存期缩短相关。
- 接受姑息治疗时,接受推荐治疗者生存超过2年的患者数约为拒绝部分或全部推荐治疗者的3倍。
研究设计与样本
- 分析美国国家癌症数据库2004至2017年间年龄≥18岁、组织学确诊为IV级胶质母细胞瘤患者的治疗模式。
- 所有统计分析基于单因素和多因素回归模型。
主要发现
- 共识别85,380例胶质母细胞瘤患者,其中2803例(3.28%)接受了姑息治疗。
- 多因素logistic回归显示,年龄≥70岁(OR 1.28;95%CI 1.04-1.58;P<0.001)、医疗保险(OR 1.348;95%CI 1.13-1.61;P=0.001)、肿瘤大小≥5 cm(OR 1.15;95%CI 1.01-1.31;P=0.036)、肿瘤多灶性(OR 1.69;95%CI 1.47-1.96;P<0.001)、肿瘤跨叶(OR 2.09;95%CI 1.13-3.86;P=0.018)、Charlson-Deyo评分>0、在非学术/研究项目接受治疗、治疗机构诊治癌症量中等(OR 1.19;95%CI 1.02-1.38;P=0.026)与接受姑息治疗几率增加独立相关。
- 家庭收入≥40,227美元和治疗机构诊治癌症量高(OR 0.75;95%CI 0.58-0.96;P=0.02)与接受姑息治疗几率降低独立相关。
- 未接受姑息治疗的患者2年总生存率长于接受姑息治疗者(22% vs 8.8%;P<0.001)。
- 在接受姑息治疗的患者中,接受推荐治疗者2年总生存率长于拒绝部分或全部推荐治疗者(9.1% vs 3.8%;P=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-grade glioma has a poor overall survival with profoundly negative effects on the patient's quality of life and their caregivers. In this study, we investigate the factors associated with receiving palliative care in patients diagnosed with glioblastoma (GBM) and the association of receiving or not receiving palliative care with overall survival. METHODS: The National Cancer Database was analyzed for patterns of care in patients ≥18 years old who were diagnosed with histologically confirmed grade IV GBM between 2004 and 2017. All statistical analyses were conducted based on univariate and multivariate regression models. RESULTS: A total of 85,380 patients with the diagnosis of GBM were identified. Of the study population, 2803 patients (3.28%) received palliative therapy. On multivariate logistic regression analysis, age ≥70 years (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.04-1.58; P < 0.001), Medicare (OR, 1.348; CI, 1.13-1.61; P = 0.001), tumor size ≥5 cm (OR, 1.15; CI, 1.01-1.31; P = 0.036), tumor multifocality (OR, 1.69; CI, 1.47-1.96; P < 0.001), lobe overlapping tumor (OR, 2.09; CI, 1.13-3.86; P = 0.018), Charlson-Deyo score >0, receiving treatment at a nonacademic/research program, and medium volume of cancers managed at the treatment facility (OR, 1.19; CI, 1.02-1.38; P = 0.026) were independent risk factors associated with an increased chance of receiving palliative care. In contrast, a household income of ≥$40,227 and high volume of cancer managed at the treatment facility (OR, 0.75; CI, 0.58-0.96; P = 0.02) were independent risk factors associated with decreased palliative care. Patients who received no palliative care had a 2-year overall survival longer than those who received palliative care (22% vs. 8.8%; P < 0.001). In patients receiving palliative care, those who received recommended treatment had a 2-year overall survival longer than those who declined part or whole recommended treatment (9.1% vs. 3.8%; P = 0.009). CONCLUSIONS: In patients with high-grade glioma, receiving palliative care is associated with decreased survival. When receiving palliative care, recommended treatment increases the number of patients who survive more than 2 years approximately 3-fold compared with those declining part or whole treatment.
引用
- Pando A, Patel AM, Choudhry HS, et al. Palliative Care Effects on Survival in Glioblastoma: Who Receives Palliative Care? World Neurosurg. 2022. PMID: 36481442. doi:10.1016/j.wneu.2022.11.143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。